Established in 1958, China Medical University (CMU) in Taichung, Taiwan, has since developed into one of the world’s premiere medical research universities with 9 colleges in total: the Colleges of Medicine, Chinese Medicine, Pharmacy, Life Sciences, Public Health, Health Care, Dentistry, Humanities and Technology, and Biomedical Engineering. Its Joint Commission International (JCI)-accredited hospitals have a total of over 6,000 beds, and it is the second largest healthcare system nationwide providing superb service of western and Chinese medicine. CMU is ranked as one of the top 300 universities by Academic Ranking of World Universities 2021, ranked top 350 by Times Higher Education (THE) World University Rankings 2021and ranked top 100 by 2021 THE Asia University Rankings.

CMU trains both western medicine doctors and Chinese medicine doctors and implements the best integration of western and Chinese medicine at CMU Hospital providing outstanding medical service to patients. As a leader in several research fields with a culture of collaboration and innovation, CMU has made important breakthroughs in cancer treatment such as inventing combined target therapy and immune checkpoint therapy to overcome difficult malignancies, lengthening the survival of glioblastoma patients, discovering ANK-199, a promising anticancer drug that treats head and neck cancer, and identifying the receptor protein IL-17RB that is strongly associated with pancreatic cancer. The Center of Excellence for Chinese Medicine is awarded with Top-Notch Center Grant by Ministry of Education (MOE) for 5 years and conducts many lines of clinical studies and discovery of mechanisms underlying the acupuncture-induced anesthesia via opioid-dependent and opioid-independent pathways. The Center of Excellence for New Drug Development is awarded with Top-Notch Center Grant by MOE and aims to develop novel drugs for 5 years.